Incyte (INCY) has expanded its partnership with Knight Therapeutics to distribute additional therapeutic drugs, including retifanlimab and axatilimab, in Latin America. Knight’s Brazilian affiliate is also seeking marketing authorization for NIKTIMVO. Incyte demonstrates strong financial health with robust profitability and liquidity, though recent insider selling warrants attention.
This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.
Incyte (INCY) Expands Latin American Partnership with Knight The
Incyte (INCY) has expanded its partnership with Knight Therapeutics to distribute additional therapeutic drugs, including retifanlimab and axatilimab, in Latin America. Knight’s Brazilian affiliate is also seeking marketing authorization for NIKTIMVO. Incyte demonstrates strong financial health with robust profitability and liquidity, though recent insider selling warrants attention.